Scarica l'app Stockscreener
132.47
0.20%
-0.26
Dopo l'orario di chiusura:
132.01
-0.46
-0.35%
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella advances QTORIN rapamycin with strong Phase 3 data, FDA review, and targets 2027 US launch. - Pluang
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger (NASDAQ:PVLA) - Seeking Alpha
Palvella Therapeutics Wins Additional US FDA Grant Funding for Rare Skin Disease Drug - Yahoo Finance
Palvella receives third year of FDA grant funding for therapy - Investing.com
A potential treatment for an estimated 30,000-plus U.S. patients could launch in 2027, if approved - Stock Titan
Palvella Therapeutics Price Target Maintained With a $240.00/Share by Chardan Capital - Moomoo
Chardan Capital maintains Buy rating on Palvella Therapeutics, $240 price target - TradingView
Palvella Therapeutics (PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss as Pipeline Spending AcceleratesEarnings Growth Analysis - careplusvn.com
Palvella (NASDAQ: PVLA) officer plans new stock sale after three recent trades - Stock Titan
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares By Investing.com - Investing.com South Africa
Palvella Therapeutics director George M Jenkins sells $4.17 million in shares - Investing.com UK
Director at Palvella Therapeutics (PVLA) sells 27,500 shares under trading plan - Stock Titan
Palvella Names James Treat CMO as QTORIN Advances Toward Market - mychesco.com
Director at Palvella Therapeutics (NASDAQ: PVLA) plans multi-million-dollar stock sale - Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - Kalkine
Mizuho Securities Keeps Their Buy Rating on Palvella Therapeutics (PVLA) - theglobeandmail.com
Palvella Therapeutics Names James Treat Chief Medical Officer Ahead of QTORIN Commercialization - citybiz
Palvella at Cantor global healthcare conference: rare-disease push By Investing.com - Investing.com India
Palvella Therapeutics Appoints James Treat, M.D., as Chief Medical Officer - Quiver Quantitative
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer - Yahoo Finance
KIRITSY CHRISTOPHER P Executes Palvella Therapeutics Options and Sells Shares at $157 on September 2, 2026 - Kalkine Media
Palvella CEO to Pitch Rare-Disease Pipeline at Investor Meets - MyChesCo
ICYMI: Palvella Seeks FDA Approval for Rare-Disease Skin Therapy - mychesco.com
Palvella Therapeutics (NASDAQ: PVLA) director exercises options, then sells 313 shares - Stock Titan
Palvella Therapeutics (NASDAQ: PVLA) investor to sell 375 shares - Stock Titan
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - The Manila Times
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Palvella Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Barchart.com
Palvella Therapeutics Completes Rolling Submission of NDA for QTORIN Rapamycin - Yahoo Finance
Hsbc Holdings PLC Invests $7.64 Million in Palvella Therapeutics, Inc. $PVLA - MarketBeat
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella (PVLA) Latest Quarter: EPS Comes in Below Forecast in the Available Record; Share Response: Shares Fall 6.03% for the Current SessionConsensus Forecast Report - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) officer plans $647K share sale - Stock Titan
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - MarketBeat
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Th - GuruFocus
First Light Asset Management (PVLA) discloses 5.34% Palvella Therapeutics stake in client accounts - Stock Titan
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
PVLA Q2 2026 Earnings: Wider-Than-Expected Loss Reflects Accelerated Clinical InvestmentEarnings Stability Report - dars.gov.et
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Prudential Financial (PVLA) reports 6.7% beneficial ownership in Palvella Therapeutics - Stock Titan
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):